Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Pfizer vaccine trial success signals breakthrough in pandemic battle

Stock Markets Nov 09, 2020 11:21PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
3/3 © Reuters. FILE PHOTO: A sign is pictured outside Pfizer Headquarters in the Manhattan borough of New York City 2/3
 
AZN
+3.20%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-0.63%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
-0.56%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
-1.76%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ZM
-3.98%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BNTX
-1.62%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Michael Erman and Julie Steenhuysen

(Reuters) - Pfizer Inc's (N:PFE) experimental COVID-19 vaccine is more than 90% effective based on initial trial results, the drugmaker said on Monday, a major victory in the war against a virus that has killed over a million people and battered the world's economy.

Scientists, public health officials and investors welcomed the first successful interim data from a large-scale clinical test as a watershed moment that could help turn the tide of the pandemic if the full trial results pan out. However, mass roll-outs, which needs regulatory approval, will not happen this year and several vaccines are seen as necessary to meet massive global needs.

Pfizer and German partner BioNTech SE (F:22UAy) said they had found no serious safety concerns yet and expected to seek U.S. emergency use authorization this month, raising the chance of a regulatory decision as soon as December.

If granted, the companies estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.

"Today is a great day for science and humanity," said Pfizer Chief Executive Albert Bourla, noting the data milestone comes with "infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen."

Experts said they wanted to see the full trial data, but the preliminary results looked encouraging.

"This news made me smile from ear to ear. It is a relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general," said Peter Horby, professor of emerging infectious diseases at the University of Oxford.

There are still many questions, such as how effective the vaccine is by ethnicity or age and how long immunity may last.

"But the bottom line is, as a vaccine it's more than 90% effective, which is extraordinary," top U.S. infectious diseases expert Dr. Anthony Fauci told CNN.

Pfizer expects to seek U.S. emergency use authorization for people aged 16 to 85. To do so, it will need two months of follow-up safety data to assure no side effects crop up. That is expected to be available in the third week of November.

U.S. Health and Human Services Secretary Alex Azar said it would take several weeks for U.S. regulators to receive and process the data before a potential approval.

MARKETS SURGE

The prospect of a vaccine electrified world markets with the S&P 500 and Dow hitting record highs. JPMorgan (NYSE:JPM) said on Monday it expected the S&P 500 index to hit 4,000 points by early 2021 and called Pfizer's COVID-19 vaccine and called Pfizer Inc's PFE.N COVID-19 vaccine update "one of the best backdrops for sustained gains in years."

Stock of theme park and film company Walt Disney (NYSE:DIS) rose 12% and movie chain operator AMC Entertainment (NYSE:AMC) Holdings was up 51%. Shares in companies that have thrived during lockdowns, such as Netflix Inc (O:NFLX) and conferencing platform Zoom Video (O:ZM) tumbled. Gun stocks sold off on higher hopes for a return to normal and a lack of civil unrest.

Pfizer shares jumped more than 8% to their highest since July last year, while BioNTech's stock hit a record high. Mizuho Securities analyst Vamil Divan forecast the vaccine may generate sales in excess of $8.5 billion for Pfizer in 2020-2021 alone.

Shares of other vaccine developers in the final stage of testing also rose with Johnson & Johnson (N:JNJ) up nearly 4% and Moderna Inc (O:MRNA), whose vaccine uses a similar technology as the Pfizer shot, up more than 8%. Britain's AstraZeneca (L:AZN), however, fell 2%.

Moderna is expected to report results from its large-scale trial later this month. "It's likely that we're going to have more than one vaccine that's effective," Fauci said.

William Schaffner, infectious diseases expert at Vanderbilt University School of Medicine in Nashville, Tennessee, called the Pfizer results better than most anticipated. "The study isn't completed yet, but nonetheless the data look very solid."

U.S. President Donald Trump welcomed the test results, and the market boost: "STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!" he tweeted.

President-elect Joe Biden said the news was excellent but did not change the fact that face masks, social distancing and other health measures would be needed well into next year.

The World Health Organization called the results very positive but warned there was a funding gap of $4.5 billion that could slow access to tests, medicines and vaccines in low- and middle-income countries.

There are other challenges as well that could affect less affluent countries. The Pfizer vaccine must be shipped and stored at an extremely cold temperature, which requires necessary infrastructure. Even many U.S. hospitals lack these super cold storage units, which may impact when and where the vaccine becomes available in many U.S. rural areas as well.

That highlights the need for more traditional vaccines in development, such as J&J's candidate.

'NEAR ECSTATIC'

Still, there was cause for jubilation.

"I'm near ecstatic," Bill Gruber, one of Pfizer's top vaccine scientists, said in an interview. "This is a great day for public health and for the potential to get us all out of the circumstances we're now in."

Between 55% and 65% of the population will need to be vaccinated to break the dynamic of the spread of COVID-19, said Germany's health minister Jens Spahn, adding that he did not expect a shot to be available before the first quarter of 2021.

The European Union said on Monday it would soon sign a contract for up to 300 million doses of the Pfizer and BioNTech COVID-19 vaccine.

The companies have a $1.95 billion contract with the U.S. government to deliver 100 million vaccine doses beginning this year. They did not receive research funding from the Trump administration's Operation Warp Speed vaccine program.

The drugmakers have also reached supply agreements with the United Kingdom, Canada and Japan.

The interim analysis, conducted after 94 participants in the trial developed COVID-19, examined how many had received the vaccine versus a placebo.

Pfizer did not provide that detail, but over 90% effective implies that no more than 8 of the 94 had received the vaccine, administered in two shots about three weeks apart.

The efficacy rate, which could drop once full results are available, is well above the 50% effectiveness required by the U.S. Food and Drug Administration for a coronavirus vaccine.

Shortly after Pfizer's announcement, Russia said its Sputnik V vaccine was also more than 90% effective, based on data collated from inoculations of the public.

MORE DATA NEEDED

To confirm the efficacy rate, Pfizer said it would continue its trial until there were 164 COVID-19 cases among volunteers. Bourla told CNBC on Monday that could be before the end of November.

Lawrence Young, a professor of molecular oncology at Britain's University of Warwick, noted that the data may show the vaccine keeps people from getting sick but not necessarily from becoming infected. "And the subtlety there ... is if you're infected then you can still transmit the virus."

Dozens of drugmakers and research groups around the globe have been racing to develop vaccines against COVID-19, which on Sunday exceeded 50 million cases since the new coronavirus first emerged late last year in China.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks, and produced at scale more rapidly than conventional vaccines. The technology is designed to trigger an immune response without using pathogens, such as actual virus particles.

The Trump administration has said it will have enough vaccine doses for all of the 330 million U.S. residents who want it by the middle of 2021.

Pfizer vaccine trial success signals breakthrough in pandemic battle
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (77)
Zainal Jalaluddin
Zainal Jalaluddin Nov 10, 2020 6:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Maybe If they announced the vaccine news before ellection. Trump would win
Bulls MakeMore
Bulls MakeMore Nov 10, 2020 6:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Did anyone else notice it's towards the end of a 4 week waiting period, there could have been news on this before the election but everything pro-Trump was surpressed for 4 years smh...Nelson Peltz on CNBC pointed out how great Trump was with the economy. jobs, and a landmark peace deal in the middle east...all surpressed in an effort to kick his non-PC *****out of Washington
Lo Lmr
Lo Lmr Nov 10, 2020 5:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
« Still, over 90% effectiveness implies that no more than 8 of the 94 had been given the vaccine » Enthousiasm really !!
Waldemar Gau
Waldemar Gau Nov 10, 2020 12:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
market manipulation this news is
Daniel Lu
Daniel Lu Nov 09, 2020 9:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sell on the trumpets
Musical Critic
Musical Critic Nov 09, 2020 8:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What happened to tha market? Did the vaccine evaporate away?????
Chic Surinthum
Chic Surinthum Nov 09, 2020 6:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
War for Trump? Why vaccine come with Joe? Who plan this for corrup american people??
Bernard Tan
Bernard Tan Nov 09, 2020 6:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Trump is fired! ☠️
Ave Joe
Ave Joe Nov 09, 2020 5:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
For some reason I don't believe this news...
Bernard Tan
Bernard Tan Nov 09, 2020 5:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fake news as Trump would have said!
Bubba Born
Bubba Born Nov 09, 2020 5:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I guess you could call '90% effective' great if the remaining 10% doesn't die from tye vaccine!
Bernard Tan
Bernard Tan Nov 09, 2020 5:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What? Only 8 out of 94? And the 8 are the youth patients?
Keith Wade
Keith Wade Nov 09, 2020 5:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not many winners around this discussion, I made 9 million dollars last night. Long live the conspiracy! BTW, to win you need to be positive, negativity will bring you undone.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email